Abstract
In 1977 an unknown natural product was isolated from Streptomyces staurosporeus by Omura et al. during a search for new alkaloids present in actinomycetes and was given the name AM-2282. Later, the structure of AM-2282 was elucidated by single crystal X-ray analysis and renamed as staurosporine. It has been published that staurosporine and its analogues display strong inhibitory effect against a variety of kinases and a number of biological properties such as antifungal, antibacterial, and immunosuppressive activities. Despite strong inhibitory activity of staurosporine, a very high level of cross-reactivity makes it impossible to use staurosporine as a therapeutic agent. In the course of searching for other staurosporine-related compounds, a number of staurosporine analogues have been isolated from different microorganisms. In addition, a number of staurosporine analogues have been synthesized to improve the poor selectivity and target specificity of staurosporine which limited its clinical effectiveness. The review addresses staurosporine analogues from both microbial and synthetic sources and their biological activities.
Keywords: Staurosporine analogues, cancer, kinase inhibitor, phosphorylation, biological activity.
Current Medicinal Chemistry
Title:Staurosporine Analogues from Microbial and Synthetic Sources and Their Biological Activities
Volume: 20 Issue: 31
Author(s): B. S. Park, A. Z. Abdel-Azeem, M. M. Al-Sanea, K. H. Yoo, J. S. Tae and S. H. Lee
Affiliation:
Keywords: Staurosporine analogues, cancer, kinase inhibitor, phosphorylation, biological activity.
Abstract: In 1977 an unknown natural product was isolated from Streptomyces staurosporeus by Omura et al. during a search for new alkaloids present in actinomycetes and was given the name AM-2282. Later, the structure of AM-2282 was elucidated by single crystal X-ray analysis and renamed as staurosporine. It has been published that staurosporine and its analogues display strong inhibitory effect against a variety of kinases and a number of biological properties such as antifungal, antibacterial, and immunosuppressive activities. Despite strong inhibitory activity of staurosporine, a very high level of cross-reactivity makes it impossible to use staurosporine as a therapeutic agent. In the course of searching for other staurosporine-related compounds, a number of staurosporine analogues have been isolated from different microorganisms. In addition, a number of staurosporine analogues have been synthesized to improve the poor selectivity and target specificity of staurosporine which limited its clinical effectiveness. The review addresses staurosporine analogues from both microbial and synthetic sources and their biological activities.
Export Options
About this article
Cite this article as:
Park S. B., Abdel-Azeem Z. A., Al-Sanea M. M., Yoo H. K., Tae S. J. and Lee H. S., Staurosporine Analogues from Microbial and Synthetic Sources and Their Biological Activities, Current Medicinal Chemistry 2013; 20 (31) . https://dx.doi.org/10.2174/09298673113209990176
DOI https://dx.doi.org/10.2174/09298673113209990176 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Codon Swapping of Zinc Finger Nucleases Confers Expression in Primary Cells and <i>In Vivo</i> from a Single Lentiviral Vector
Current Gene Therapy Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Advances in the Study of Mammalian Proteome by Tandem Affinity Purification – Mass Spectrometry
Current Proteomics Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma
Current Molecular Medicine Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Anti-HIV Factors: Targeting Each Step of HIV’s Replication Cycle
Current HIV Research Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry The Complex Airway in Childhood Asthma
Current Pediatric Reviews Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT
Current Medicinal Chemistry Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Current Pharmaceutical Design Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry Anti-inflammatory Activity of Extra Virgin Olive Oil Polyphenols: Which Role in the Prevention and Treatment of Immune-Mediated Inflammatory Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™, ET-743)
Current Clinical Pharmacology Transposable Elements and their Use for Target Site Specific Gene Delivery
Current Pharmacogenomics IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews